Apalutimide Plus ADT Improves Survival in Nonmetastatic Castration-Resistant Prostate Cancer

Final data analysis of SPARTAN trial demonstrates large benefit in overall survival when compared with ADT plus placebo.

Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news